Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study reveals significant gaps in MMR vaccine knowledge among ER patients

20

Apr 2026

Study reveals significant gaps in MMR vaccine knowledge among ER patients

Measles remains one of the most contagious infectious diseases, spread through coughing and sneezing, with even small declines in vaccination coverage leading to outbreaks. As of 2026, California has reported its highest annual measles case count in seven years. In response to this growing concern, researchers have begun examining gaps in measles-related knowledge and vaccination coverage.

Global proteomics data sharing grows fast as ProteomeXchange scales up

20

Apr 2026

Global proteomics data sharing grows fast as ProteomeXchange scales up

ProteomeXchange’s 2026 update shows that global proteomics data sharing continues to accelerate, with more than 64,000 datasets submitted and nearly half added in just the last three years. The paper also highlights how standards, reuse tools, and AI-ready resources are helping make mass spectrometry proteomics data more findable, accessible, and reusable.

Teen cannabis use linked to slower growth in memory and thinking

20

Apr 2026

Teen cannabis use linked to slower growth in memory and thinking

Researchers from University of California San Diego have found that teenagers who begin using cannabis show slower gains in thinking and memory skills as they grow. The study, published on April 20, 2026 in Neuropsychopharmacology, analyzed data from more than 11,000 participants in the Adolescent Brain Cognitive Development (ABCD) Study, the largest long-term study of brain development in U.S. youth.

New study reveals CRISPR enzyme that responds to human DNA methylation

20

Apr 2026

New study reveals CRISPR enzyme that responds to human DNA methylation

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of scientists from Wageningen University & Research and Van Andel Institute has identified a way to exploit this distinction. Using a variant of CRISPR, a modern tool for editing DNA, they distinguished tumor DNA from healthy DNA and selectively cut only the former. The study, published today in Nature, is an early but promising step toward a cancer therapy that targets and destroys tumor cells with high precision.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.